Profile data is unavailable for this security.
About the company
Piramal Pharma Limited is a global pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. It operates approximately 17 development and manufacturing facilities across India, the United Kingdom/Europe, and North America. It has a commercial presence in over 100 countries. The Company operates under three business verticals: Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization (CDMO); Piramal Critical Care (PCC), a Complex Hospital Generics (CHG) business; and Piramal Consumer Healthcare business, selling over-the-counter products. PPS caters to both drug substances - Active Pharmaceutical Ingredients (APIs), and drug products (formulations). PCC's complex hospital product portfolio comprises hospital-focused products in the areas of inhalation anesthesia, intrathecal therapy, injectable anesthesia and pain management, and other generic and specialty products.
- Revenue in INR (TTM)88.71bn
- Net income in INR-1.64bn
- Incorporated2020
- Employees7.13k
- LocationPiramal Pharma LtdGr. Flr.,Piramal AnantaAgastya Corporate Park,, Kamani JunctioMUMBAI 400070IndiaIND
- Phone+91 223802300
- Websitehttps://www.piramal.com/businesses/piramal-pharma/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alivus Life Sciences Ltd | 25.12bn | 5.44bn | 112.22bn | 2.20k | 20.67 | -- | 18.25 | 4.47 | 44.23 | 44.23 | 204.37 | -- | -- | -- | -- | 11,403,810.00 | -- | 17.43 | -- | 23.95 | 57.08 | 53.29 | 21.64 | 20.24 | -- | 133.39 | -- | 27.09 | 4.54 | 9.20 | 3.13 | 9.18 | 26.57 | -- |
| Cohance Lifesciences Ltd | 20.51bn | 2.02bn | 115.99bn | 1.21k | 52.26 | -- | 33.78 | 5.65 | 5.80 | 5.80 | 58.32 | -- | -- | -- | -- | 16,926,160.00 | -- | 18.62 | -- | 20.90 | 71.62 | 60.82 | 8.80 | 30.28 | -- | 7.07 | -- | 15.59 | 13.91 | 7.51 | -10.79 | -3.31 | 9.39 | -- |
| Concord Biotech Ltd | 11.59bn | 3.12bn | 125.63bn | 1.57k | 40.42 | -- | 33.00 | 10.84 | 29.71 | 29.71 | 110.27 | -- | -- | -- | -- | 7,375,525.00 | -- | 18.47 | -- | 20.61 | 57.97 | 67.80 | 26.85 | 30.22 | -- | -- | -- | 20.68 | 18.01 | 18.56 | 20.62 | 17.06 | -6.49 | -- |
| Caplin Point Laboratories Ltd | 20.89bn | 6.14bn | 127.16bn | 990.00 | 20.78 | -- | 18.35 | 6.09 | 80.49 | 80.49 | 274.05 | -- | -- | -- | -- | 21,105,860.00 | -- | 19.10 | -- | 21.90 | 60.67 | 54.95 | 29.77 | 26.11 | -- | 1,127.02 | -- | 8.93 | 14.37 | 17.55 | 17.33 | 20.06 | 20.07 | 19.14 |
| Jubilant Pharmova Ltd | 79.18bn | 4.33bn | 134.67bn | 978.00 | 31.23 | -- | 15.88 | 1.70 | 27.23 | 27.23 | 498.28 | -- | -- | -- | -- | 80,965,230.00 | -- | 3.37 | -- | 4.02 | 67.71 | 64.54 | 5.42 | 5.64 | -- | 4.06 | -- | 21.60 | 7.93 | 3.90 | 988.72 | 6.73 | 14.21 | 0.00 |
| Alembic Pharmaceuticals Ltd | 72.67bn | 6.29bn | 138.63bn | 16.57k | 22.00 | -- | 14.99 | 1.91 | 32.06 | 32.06 | 370.42 | -- | -- | -- | -- | 4,385,258.00 | -- | 9.51 | -- | 12.59 | 72.71 | 65.30 | 8.61 | 10.84 | -- | 8.89 | -- | 33.08 | 7.12 | 7.69 | -5.26 | -6.78 | -5.17 | 9.46 |
| Granules India Ltd | 50.92bn | 5.45bn | 142.33bn | 4.07k | 25.55 | -- | 17.29 | 2.80 | 22.48 | 22.48 | 209.84 | -- | -- | -- | -- | 12,524,500.00 | -- | 10.20 | -- | 15.66 | 64.46 | 50.89 | 10.71 | 11.64 | -- | 6.98 | -- | 8.72 | -0.5494 | 11.52 | 23.74 | 9.64 | 25.38 | 8.45 |
| Neuland Laboratories Ltd | 15.75bn | 1.79bn | 168.02bn | 1.80k | 93.80 | -- | 63.97 | 10.67 | 139.62 | 139.62 | 1,227.57 | -- | -- | -- | -- | 8,755,392.00 | -- | 11.09 | -- | 14.93 | 49.33 | 49.56 | 11.37 | 14.20 | -- | 12.29 | -- | 6.80 | -5.24 | 14.13 | -13.32 | 45.82 | 33.44 | 43.10 |
| Natco Pharma Ltd | 45.60bn | 15.57bn | 171.27bn | 4.20k | 11.00 | -- | 9.52 | 3.76 | 86.94 | 86.94 | 254.62 | -- | -- | -- | -- | 10,860,210.00 | -- | 15.82 | -- | 18.14 | 82.79 | 75.22 | 33.87 | 30.39 | -- | 44.51 | -- | 12.09 | 10.77 | 18.26 | 35.81 | 32.55 | 7.37 | -2.33 |
| Eris Lifesciences Ltd | 30.78bn | 4.31bn | 188.45bn | 3.56k | 43.03 | -- | 24.86 | 6.12 | 31.61 | 31.61 | 225.62 | -- | -- | -- | -- | 8,651,377.00 | -- | 9.98 | -- | 13.50 | 74.64 | 77.74 | 15.28 | 20.85 | -- | 4.06 | -- | -- | 44.02 | 21.92 | -10.24 | 3.48 | 0.4868 | -- |
| Piramal Pharma Ltd | 88.71bn | -1.64bn | 202.22bn | 7.13k | -- | -- | 29.22 | 2.28 | -1.26 | -1.26 | 66.90 | -- | -- | -- | -- | 12,449,300.00 | -- | -- | -- | -- | 64.63 | -- | -1.84 | -- | -- | 0.5519 | -- | -- | 11.99 | -- | 411.39 | -- | -- | -- |
| Sai Life Sciences Ltd | 21.70bn | 3.33bn | 211.00bn | 3.40k | 64.40 | -- | 42.89 | 9.72 | 15.47 | 15.47 | 100.85 | -- | -- | -- | -- | 6,380,065.00 | -- | -- | -- | -- | 73.41 | -- | 15.34 | -- | -- | 10.74 | -- | -- | 15.66 | -- | 105.45 | -- | -- | -- |
| Wockhardt Ltd | 31.51bn | 220.00m | 212.86bn | 2.30k | 990.09 | -- | 90.58 | 6.76 | 1.32 | 1.32 | 194.54 | -- | -- | -- | -- | 13,723,870.00 | -- | -4.37 | -- | -7.67 | 65.92 | 56.50 | 0.2539 | -11.98 | -- | 1.23 | -- | -- | 7.65 | 1.15 | 89.85 | -- | 16.19 | -- |
| Astrazeneca Pharma India Ltd | 21.77bn | 2.01bn | 220.03bn | 802.00 | 109.49 | -- | 91.09 | 10.10 | 80.38 | 80.38 | 871.22 | -- | -- | -- | -- | 27,150,250.00 | -- | 11.06 | -- | 18.24 | 42.78 | 49.98 | 9.23 | 9.43 | -- | 78.86 | -- | 38.57 | 32.48 | 15.59 | -28.34 | 9.89 | -34.23 | 100.00 |
| Pfizer Ltd | 24.82bn | 8.54bn | 224.69bn | 1.60k | 26.32 | -- | 24.61 | 9.05 | 186.60 | 186.60 | 542.67 | -- | -- | -- | -- | 15,533,980.00 | -- | 15.22 | -- | 18.50 | 65.10 | 61.73 | 34.39 | 25.99 | -- | 83.13 | -- | 50.95 | 4.02 | 1.18 | 39.23 | 8.56 | -6.02 | 28.47 |
| Emcure Pharmaceuticals Ltd | 88.50bn | 8.70bn | 273.99bn | 6.73k | 31.48 | -- | 21.07 | 3.10 | 45.91 | 45.91 | 467.02 | -- | -- | -- | -- | 13,148,240.00 | -- | 8.47 | -- | 15.86 | 59.93 | 59.30 | 10.11 | 8.99 | -- | 30.68 | -- | 0.00 | 18.59 | 9.36 | 36.76 | 52.13 | 21.35 | -- |
Data as of Mar 02 2026. Currency figures normalised to Piramal Pharma Ltd's reporting currency: Indian Rupee INR
17.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 26 Jun 2025 | 120.08m | 9.03% |
| East Bridge Capital Management L.P.as of 31 Dec 2025 | 26.64m | 2.00% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 24.08m | 1.81% |
| Canara Robeco Asset Management Co., Ltd. (Invt Mgmt)as of 31 Jan 2026 | 14.56m | 1.10% |
| Bandhan AMC Ltd.as of 31 Jan 2026 | 9.80m | 0.74% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 9.71m | 0.73% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 9.35m | 0.70% |
| Franklin Templeton Asset Management (India) Pvt Ltd.as of 30 Jan 2026 | 7.79m | 0.59% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 6.46m | 0.49% |
| Bajaj Finserv Asset Management Ltd.as of 31 Jan 2026 | 5.98m | 0.45% |
More ▼
Data from 31 Dec 2025 - 15 Feb 2026Source: FactSet Research Systems Inc.
